We use cookies on our website, which are text files containing small amounts of information that are downloaded to your computer or mobile device. To find out more about the cookies we use please click here.

Some of these cookies are strictly necessary for operation of this site. Other, non-essential cookies are used for measuring website performance (which is all aggregated and anonymised) and may share this information with Google. To consent to non-essential cookies, click "Accept all non-essential cookies".

PsiOxus aims to be the world’s leading immuno-oncolytic virus company, delivering medicines of value to patients with cancer.

PsiOxus Therapeutics is a development stage biotechnology company using non-traditional approaches to develop novel therapeutics that address cancer and other clinically unmet diseases.

MT-102, a dual action Anabolic Catabolic Transforming Agent (ACTA), is in phase II clinical development for the treatment of cachexia. ColoAd1, an oncolytic virus for the systemic treatment of metastatic cancer, has demonstrated optimal anti-cancer properties in late pre-clinical development.

The company is also developing treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines.

Other portfolio companies

© Mercia Technologies 2018

Terms and conditions Privacy policy

Designed and built by Onespacemedia